Piramal Life Sciences Limited - Product Pipeline Review - H2 2011

Global Markets Direct, September 2011, Pages: 49

Piramal Life Sciences Limited – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Piramal Life Sciences Limited – Product Pipeline Review – H2 2011” provides data on the Piramal Life Sciences Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Piramal Life Sciences Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Piramal Life Sciences Limited and industry–specific third party sources, put together by Global Markets Direct’s team.

Scope

- Piramal Life Sciences Limited - Brief Piramal Life Sciences Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Piramal Life Sciences Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Piramal Life Sciences Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Piramal Life Sciences Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Piramal Life Sciences Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Piramal Life Sciences Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Piramal Life Sciences Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Piramal Life Sciences Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Piramal Life Sciences Limited and identify potential opportunities in those areas.

List of Tables
List of Figures
Piramal Life Sciences Limited Snapshot
Piramal Life Sciences Limited Overview
Key Information
Key Facts
Piramal Life Sciences Limited – Research and Development Overview
Key Therapeutic Areas
Piramal Life Sciences Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Piramal Life Sciences Limited – Pipeline Products Glance
Piramal Life Sciences Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Piramal Life Sciences Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Piramal Life Sciences Limited – Drug Profiles
DGAT1
Product Description
Mechanism of Action
R&D Progress
IL6
Product Description
Mechanism of Action
R&D Progress
Microbial Leads
Product Description
Mechanism of Action
R&D Progress
P1201
Product Description
Mechanism of Action
R&D Progress
P2202
Product Description
Mechanism of Action
R&D Progress
P276
Product Description
Mechanism of Action
R&D Progress
P276-00 + Gemcitabine + Carboplatin
Product Description
Mechanism of Action
R&D Progress
P3914
Product Description
Mechanism of Action
R&D Progress
PI3 kinase
Product Description
Mechanism of Action
R&D Progress
PM181104
Product Description
Mechanism of Action
R&D Progress
Target X
Product Description
Mechanism of Action
R&D Progress
Target Y
Product Description
Mechanism of Action
R&D Progress
TNF alpha
Product Description
Mechanism of Action
R&D Progress
Piramal Life Sciences Limited – Pipeline Analysis
Piramal Life Sciences Limited – Pipeline Products by Therapeutic Class
Piramal Life Sciences Limited - Pipeline Products By Target
Piramal Life Sciences Limited – Pipeline Products by Route of Administration
Piramal Life Sciences Limited – Pipeline Products by Molecule Type
Piramal Life Sciences Limited – Recent Pipeline Updates
Piramal Life Sciences Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 28, 2008: Piramal Life Sciences Obtains Approval For Initiation Of Phase I Trials Of New Cancer Molecule P-1446A-05 In Canada
Feb 26, 2008: Piramal Life Sciences Initiates Phase I Clinical Study Of P1201-07, In The Netherlands
Aug 25, 2009: Piramal Life Sciences Completes Phase I Trials With A New Molecule For Type II Diabetes In Europe
May 20, 2009: Piramal Life Sciences Commences Phase I Trial On New Molecule Of Diabetes-Metabolic Syndrome In Canada
Oct 16, 2008: Piramal Life Sciences Begins Phase II Trial Of P276 For Head And Neck Cancer
Sep 16, 2009: Piramal Life Sciences Presents Data From Preclinical Studies Of PM181104 At ICAAC Convention In The USA
Jan 15, 2009: Piramal Life Sciences Initiates Phase II Trials Of P276 For Mantle Cell Lymphoma
Oct 13, 2008: Piramal Life Sciences Receives DCGI Approval To Conduct Phase I Trial Of New Cancer Molecule P-1446A-05 In India
May 13, 2008: Piramal Life Sciences Initiates Phase I Trials With P1736 For Type II Diabetes In Europe
May 12, 2009: Piramal Life Sciences Receives DCGI Approval To Conduct Two Phase I/II Combination Trials Of P276 For Pancreatic, And Head And Neck Cancer In India
Jun 09, 2008: Piramal Life Sciences Makes Oral Presentation On Breakthrough Molecule For Type II Diabetes At ADA Convention
Mar 09, 2010: Piramal Life Sciences Introduces Tinefcon At American Academy Of Dermatology Convention For Treatment Of Psoriasis
Financial Deals Landscape
Piramal Life Sciences Limited, Deals Summary, 2004 to 2011
Piramal Life Sciences Limited Detailed Deal Summary
Piramal Life Sciences Enters Into Agreement With Eli Lilly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Piramal Life Sciences Limited – Pipeline by Therapy Area and Indication, H2 2011
Piramal Life Sciences Limited – Pipeline by Stage of Development, H2 2011
Piramal Life Sciences Limited – Monotherapy Products in Pipeline, H2 2011
Piramal Life Sciences Limited – Combination Treatment Modalities in Pipeline, H2 2011
Piramal Life Sciences Limited - Phase II, H2 2011
Piramal Life Sciences Limited - Phase I, H2 2011
Piramal Life Sciences Limited - Pipeline By Therapeutic Class, H2 2011
Piramal Life Sciences Limited - Pipeline By Target, H2 2011
Piramal Life Sciences Limited – Pipeline By Route of Administration, H2 2011
Piramal Life Sciences Limited – Pipeline By Molecule Type, H2 2011
Piramal Life Sciences Limited – Recent Pipeline Updates, H2 2011
Piramal Life Sciences Limited, Other Locations
Piramal Life Sciences Limited, Deals Summary, 2004 to 2011

List of Figures
Piramal Life Sciences Limited – Pipeline by Therapy Area and Indication, H2 2011
Piramal Life Sciences Limited – Pipeline by Stage of Development, H2 2011
Piramal Life Sciences Limited – Monotherapy Products in Pipeline, H2 2011
Piramal Life Sciences Limited – Combination Treatment Modalities in Pipeline, H2 2011
Piramal Life Sciences Limited – Pipeline By Therapeutic Class, H2 2011
Piramal Life Sciences Limited - Pipeline By Target, H2 2011
Piramal Life Sciences Limited – Pipeline By Route of Administration, H2 2011
Piramal Life Sciences Limited – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile